Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | STAT6 | P42226 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | APEX1 | P27695 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | FBP1 | P09467 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11301188 | 0.87 | CYP1A2 (0.63) | CYP1A2CYP2D6CYP2C19MAPK1CYP3A4 | |
| SCHEMBL819078 | 0.87 | CYP1A2 (0.63) | CYP1A2CYP2D6CYP2C19MAPK1CYP3A4 | |
| SCHEMBL14138445 | 0.84 | MAPT (0.64) | CYP1A2CYP2D6CYP2C19MAPK1CYP3A4 | |
| SCHEMBL818985 | 0.83 | CYP1A2 (0.67) | CYP1A2CYP2D6CYP2C19MAPK1CYP3A4 | |
| SCHEMBL13768047 | 0.83 | CYP1A2 (0.67) | CYP1A2CYP2D6CYP2C19MAPK1CYP3A4 | |
| SCHEMBL774785 | 0.81 | CYP1A2 (0.73) | CYP1A2CYP2D6CYP2C19MAPK1CYP3A4 | |
| SCHEMBL5837665 | 0.80 | CYP1A2 (1.00) | CYP1A2CYP2D6CYP2C19MAPK1CYP3A4 | |
| SCHEMBL20279671 | 0.80 | MAPT (0.56) | CYP1A2CYP2D6CYP2C19MAPK1CYP3A4 | |
| SCHEMBL10535176 | 0.80 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP2C19MAPK1CYP3A4 | |
| SCHEMBL17363024 | 0.79 | MAPT (0.58) | CYP1A2CYP2D6CYP2C19MAPK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410078-B2 | Composition and methods to treat cardiac diseases | UNIVERSITY OF CONNECTICUT (US) | 2013-04-02 | — | — | US | disclosed |
| US-7790735-B2 | Methanocarba cycloalkyl nucleoside analogues | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2049127-A2 | N-METHANOCARBA DERIVATIVES TO TREAT CARDIAC DISEASES | University of Connecticut (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2007139775-A2 | N-METHANOCARBA DERIVATIVES TO TREAT CARDIAC DISEASES | UNIVERSITY OF CONNECTICUT (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281908-A1 | COMPOSITION AND METHODS TO TREAT CARDIAC DISEASES | UNIVERSITY OF CONNECTICUT (US) | 2007-12-06 | — | — | US | disclosed |
| US-20060270629-A1 | Methanocarba cycloalkyl nucleoside analogues | Govt of the U.S.A., represented by the Secretary, Dept of Health & Human Services (US) | 2006-11-30 | — | — | US | disclosed |
| EP-1252160-B1 | METHANOCARBA CYCLOALKYL NUCLEOSIDE ANALOGUES | US GOV HEALTH & HUMAN SERV (US) | 2006-08-16 | — | — | EP | disclosed |
| US-7087589-B2 | Methanocarba cycloakyl nucleoside analogues | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-08-08 | — | — | US | disclosed |
| US-20030216412-A1 | Methanocarba cycloakyl nucleoside analogues | HEALTH AND HUMAN SERVICES, GOVERNMENT OF THE UNITED STATES OF AMERICA, THE, REPRESENTED BY THE SECRETARY, DEPARTMENT OF | 2003-11-20 | — | — | US | disclosed |
| EP-1252160-A1 | METHANOCARBA CYCLOALKYL NUCLEOSIDE ANALOGUES | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001051490-A1 | METHANOCARBA CYCLOALKYL NUCLEOSIDE ANALOGUES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216412-A1 | Methanocarba cycloakyl nucleoside analogues | P2RY1, ADORA1, ADORA2A | CYP1A2 1312/4885CYP2D6 1952/4885CYP2C19 1278/4885 |
| US-20070281908-A1 | COMPOSITION AND METHODS TO TREAT CARDIAC DISEASES | P2RX2, P2RX3, ATP2A1 | CYP1A2 3550/4885CYP2D6 4312/4885CYP2C19 3335/4885 |
| US-20060270629-A1 | Methanocarba cycloalkyl nucleoside analogues | ADORA2A, ADORA1, ADORA2B | CYP1A2 778/4885CYP2D6 1580/4885CYP2C19 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.